Comparison of the effects of clofibrate and halofenate (MK-185) in isolated rat hepatocytes
- 30 June 1974
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 19 (3), 381-391
- https://doi.org/10.1016/s0021-9150(74)80003-1
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Effects of ethylp‐chlorophenoxyisobutyrate on biliary secretion of bile acids, cholesterol and phosphatidyl cholineLipids, 1972
- Clinical evaluation of MK‐185: A new hypolipidemic drugLipids, 1972
- Inhibition of hepatic triglyceride formation by clofibrateJCI Insight, 1971
- Hypolipidemic, uricosuric, and thyroxine‐displacing effects of MK‐185 (halofenate)Clinical Pharmacology & Therapeutics, 1971
- On the Mode of Action of Lipid-lowering AgentsPublished by Elsevier ,1971
- Long-Term Effects of Clofibrate (Atromid-S) on Serum Lipids in ManCirculation, 1969
- Effects of chlorophenoxyisobutyrate (CPIB) on liver composition and triglyceride synthesis in ratsJournal of Atherosclerosis Research, 1966
- Studies with ethyl chlorophenoxyisobutyrate (clofibrate)Metabolism, 1965
- Effects of α-p-chlorophenoxyisobutyryl ethyl ester (CPIB) with and without androsterone on cholesterol biosynthesis in rat liverJournal of Lipid Research, 1965
- Modification of Metabolism and Distribution of Lipids by Ethyl ChlorophenoxyisobutyrateNature, 1962